A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans.

Journal: Pharmaceutical research
PMID:

Abstract

PURPOSE: Recently, there has been rapid development in model-informed drug development, which has the potential to reduce animal experiments and accelerate drug discovery. Physiologically based pharmacokinetic (PBPK) and machine learning (ML) models are commonly used in early drug discovery to predict drug properties. However, basic PBPK models require a large number of molecule-specific inputs from in vitro experiments, which hinders the efficiency and accuracy of these models. To address this issue, this paper introduces a new computational platform that combines ML and PBPK models. The platform predicts molecule PK profiles with high accuracy and without the need for experimental data.

Authors

  • Yuelin Li
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
  • Zonghu Wang
    XtalPi Innovation Center, XtalPi Inc., Beijing, 100080, China.
  • Yuru Li
    XtalPi Innovation Center, XtalPi Inc., Beijing, 100080, China.
  • Jiewen Du
    Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, 132 East Circle at University City, Guangzhou, 510006, China.
  • Xiangrui Gao
    XtalPi Innovation Center, XtalPi Inc., Beijing, 100080, China.
  • Yuanpeng Li
    Guangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Jinan University, Guangzhou 510632, China; Department of Optoelectronic Engineering, Jinan University, Guangzhou 510632, China.
  • Lipeng Lai
    XtalPi Innovation Center, XtalPi Inc., Beijing, 100080, China. lipeng@xtalpi.com.